SEATTLE, WA--(Marketwired - Feb 27, 2015) - Atossa Genetics Inc. (NASDAQ: ATOS), the Breast Care Company, announced today that its subsidiary, The National Reference Laboratory for Breast Health (the NRLBH), has received accreditation from the College of American Pathologists (CAP), which is awarded to facilities that meet the highest standards of excellence in quality laboratory practices. The NRLBH is also certified by the Centers for Medicare and Medicaid Services' Clinical Laboratory Improvements Amendment (CLIA) and holds various state licenses.

The NRLBH was assigned CAP number 8016287. The NRLBH, located in Seattle, Washington, currently provides pharmacogenomics testing and cytology testing of nipple aspirate fluid.

According to the College of American Pathologists, "The CAP Laboratory Accreditation Program is an internationally recognized program and the only one of its kind that utilizes teams of practicing laboratory professionals as inspectors. Designed to go well beyond regulatory compliance, the program helps laboratories achieve the highest standards of excellence to positively impact patient care. The program also covers a complete array of disciplines and testing procedures. Because of its comprehensive nature, CAP accreditation can help achieve a consistently high level of service throughout an institution or healthcare system. The Centers for Medicare and Medicaid Services (CMS) has granted the CAP Laboratory Accreditation Program deeming authority. It is also recognized by the Joint Commission, and can be used to meet many state certification requirements."

Dr. Steven Quay, Chairman, CEO & President of Atossa Genetics, said, "We are extremely proud to receive CAP accreditation. This national recognition reaffirms NRLBH's commitment to providing the highest quality laboratory services and reliable testing results to its clients, and is reflective of our focus on helping healthcare providers take better care of patients and improve their medical conditions."

About Atossa Genetics

Atossa Genetics Inc. is focused on improving breast health through the development of laboratory services, medical devices and therapeutics. The laboratory services are being developed by its subsidiary, the NRLBH. The laboratory services and the Company's medical devices are being developed so they can be used as companions to therapeutics to treat various breast health conditions. For more information, please visit

Forward-Looking Statements

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, the outcome or timing of regulatory approvals needed by Atossa to sell its products, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, recalls of products, the safety and efficacy of Atossa's products and services, performance of distributors, whether Atossa can launch in the United States and foreign markets the additional tests, devices and therapeutics in its pipeline in a timely and cost effective manner, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.